Pharmacokinetics and pharmacodynamics of the novel PAR-1 antagonist vorapaxar in patients with end-stage renal disease. - Wikidata - awgldk - TriplyDB

Pharmacokinetics and pharmacodynamics of the novel PAR-1 antagonist vorapaxar in patients with end-stage renal disease.

Pharmacokinetics and pharmacodynamics of the novel PAR-1 antagonist vorapaxar in patients with end-stage renal disease.

http://www.wikidata.org/entity/Q42635425

about

Impact of selective platelet inhibition in reducing cardiovascular risk - role of vorapaxar Vorapaxar: A novel agent to be considered in the secondary prevention of myocardial infarction Clinical potential of vorapaxar in cardiovascular risk reduction in patients with atherosclerosis Targeting platelet thrombin receptor signaling to prevent thrombosis.Novel anti-platelet agents: focus on thrombin receptor antagonists.Vorapaxar: first global approval.Vorapaxar in atherosclerotic disease management.Role for Thrombin Receptor Antagonism With Vorapaxar in Secondary Prevention of Atherothrombotic Events: From Bench to Bedside.Platelet thrombin receptor antagonism with vorapaxar: pharmacology and clinical trial development.Review of vorapaxar for the prevention of atherothrombotic events.Clopidogrel, prasugrel, ticagrelor or vorapaxar in patients with renal impairment: do we have a winner?Vorapaxar: The Current Role and Future Directions of a Novel Protease-Activated Receptor Antagonist for Risk Reduction in Atherosclerotic Disease.Oral antiplatelet drugs in patients with chronic kidney disease (CKD): a review.The effect of multiple doses of ketoconazole or rifampin on the single- and multiple-dose pharmacokinetics of vorapaxar.No Pharmacokinetic Drug-Drug Interaction Between Prasugrel and Vorapaxar Following Multiple-Dose Administration in Healthy Volunteers.

P2860

Q26745754-7243D973-2FD3-4B91-B094-35A393792C83 Q26748682-1F63FC4D-1C3A-421C-B1E2-096709159A47 Q26783034-C9DC967B-8457-4656-AF6B-FD8990E1765B Q37280316-1971F3C2-A1DD-4CD6-B5D7-D6F813325811 Q38084159-799E59AD-0EB5-40D3-9728-E1A9E20E1C27 Q38223033-B93FAC15-B9E9-428C-B9E1-785A68FAC09F Q38355060-042DAFFD-EF69-4C77-B8A1-4628AD87FB6F Q38402334-B13D8CCB-10B0-45BE-911D-F23451F99798 Q38592772-E6D78E08-D16C-416D-A295-5DB9D9D32797 Q38610947-72FF4BC8-78B7-4B08-A8CC-C8F70105B1C9 Q38619150-6A6DFCB1-B648-416A-BFF8-F223F10D6F62 Q38773641-9BA673BC-61BD-4961-B6F5-AFAA57A98616 Q39147420-CCEAC888-5469-4064-AFAF-AA650C1FA909 Q45847034-2EEF8D86-FC99-4E75-A6AA-077F186AB455 Q49522878-D7DDAA68-69A8-4FEF-9F4A-24775A42B0E6

P2860

Pharmacokinetics and pharmacodynamics of the novel PAR-1 antagonist vorapaxar in patients with end-stage renal disease.

http://www.wikidata.org/entity/Q42635425

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Pharmacokinetics and pharmacod ...... with end-stage renal disease.

@en

Pharmacokinetics and pharmacod ...... with end-stage renal disease.

@nl

type

label

Pharmacokinetics and pharmacod ...... with end-stage renal disease.

@en

Pharmacokinetics and pharmacod ...... with end-stage renal disease.

@nl

prefLabel

Pharmacokinetics and pharmacod ...... with end-stage renal disease.

@en

Pharmacokinetics and pharmacod ...... with end-stage renal disease.

@nl

P1433

Q42635425-8FB4CD08-9BA6-4C3B-975B-02FE72D2D555

P1476

Q42635425-1869FCF2-6450-4933-A345-8521A93443A8

P2093

Q42635425-0A633552-4D6E-4860-9F12-ED064670CA23

Q42635425-187FE6A0-D4C3-4E5D-A1DA-B5A83A01F817

Q42635425-3FB516A0-7180-4F99-B853-749BB9AF7A7F

Q42635425-61368953-7C87-468C-9982-741E626D8C75

Q42635425-66520179-6BCC-412B-AD6B-AB8B5E320670

Q42635425-8BB1AF1A-FC43-4AFC-8F99-9E8D2D874B0D

Q42635425-A1D6E3AA-941C-4489-AF6F-D35A04462E06

Q42635425-BC55BDAB-0526-4A27-8EBD-DCE5FB31360B

Q42635425-FB566FD7-373F-4FDF-BE74-8EAA1A666F63

P2860

Q42635425-034BCD4B-D472-40F9-A8CF-92F6E58ECB15

Q42635425-082BD0F7-C454-42A6-952D-3526B53B2948

Q42635425-0E55BA3D-2451-4248-86E8-B50ED07633E4

Q42635425-1222DA99-D9D9-4E40-82E1-9F6B2AE1A764

Q42635425-2BC80B51-E9C3-4B40-AFAC-8AACB8F81794

Q42635425-46D942ED-9865-42F5-9CDE-1371D411BF10

Q42635425-54B96ED4-1BF4-41AF-8265-C70BE989DE01

Q42635425-6717C676-3BE3-45B3-83E3-382168CEC8E5

Q42635425-795ABBF8-2B3A-4711-854F-5AC1B491F992

Q42635425-79ADD969-4075-444C-9E3F-755149085AB7

P2888

Q42635425-C9401902-C876-4617-8226-0DEDE233CC89

P304

Q42635425-FCF56C39-C6D0-4F74-A2DF-EEBF229C67A0

P31

Q42635425-EFF039CF-B624-4AB2-8AEB-2853E79A9C3A

P356

Q42635425-0CA40644-DA38-4E72-91B8-9B176ABCE09E

P433

Q42635425-81C13110-2E56-4FEC-B4DA-A26EFB695CB4

P478

Q42635425-A1B03DF2-71A1-452F-8E39-AE2D12F3E085

P50

Q42635425-07A1C03B-FF19-44A5-BB8D-2219284CF071

P577

Q42635425-52E14FDD-A89E-4CB6-BD6A-1DB21A54BC3B

P698

Q42635425-AC65C6FC-E389-4A79-ABA2-209E521BF365

P356

S00228-012-1217-6

P1433

European Journal of Clinical Pharmacology

P1476

Pharmacokinetics and pharmacod ...... with end-stage renal disease.

@en

P2093

Bharath Kumar

http://www.w3.org/2001/XMLSchema#string

David L Cutler

http://www.w3.org/2001/XMLSchema#string

Fengjuan Xuan

http://www.w3.org/2001/XMLSchema#string

James E Schiller

http://www.w3.org/2001/XMLSchema#string

Lei Ma

http://www.w3.org/2001/XMLSchema#string

Lisa K Jennings

http://www.w3.org/2001/XMLSchema#string

Paul Statkevich

http://www.w3.org/2001/XMLSchema#string

Ronald B Langdon

http://www.w3.org/2001/XMLSchema#string

Teddy Kosoglou

http://www.w3.org/2001/XMLSchema#string

P2860

Protease-activated receptor 1 is the primary mediator of thrombin-stimulated platelet procoagulant activity

Unstable angina pectoris

Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation

Recent advances in antiplatelet agents

Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events

Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration

A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee

ABC of antithrombotic therapy: Antithrombotic therapy for cerebrovascular disorders

G-protein coupled receptor antagonists-1: protease activated receptor-1 (PAR-1) antagonists as novel cardiovascular therapeutic agents.

Thrombin formation.

P2888

s00228-012-1217-6

P304

1049-1056

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00228-012-1217-6

http://www.w3.org/2001/XMLSchema#string

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

68

http://www.w3.org/2001/XMLSchema#string

P50

Walter K. Kraft

P577

2012-02-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22315147

http://www.w3.org/2001/XMLSchema#string